Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma - European Medical Journal

Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma. Daratumumab is a novel therapeutic human CD38 monoclonal antibody.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given